AllDocs -> cancers

Volume 1, Issue 2 Spring 2001 8 Health Watch PACE/Queens College WHPP Health Watch Spring 2001 Vol. 1 Issue 2 Written, Edited and Compiled by: Sylvia Kieding, B.A. Kim Knowlton, MS Amy Manowitz, MPH Steve Markowitz, MD Lyndon Rose, MD, MPH Other Contributing Authors David Fry Mark Griffon This newsletter has been made possible through funding from the Department of Energy, contracts: DEF-FC03-96 SF 21260, DE-FC03-97S F21512, awarded to PACE International Union. In October 2000, the PACE Worker Health Protection Program conducted the first early lung cancer detection screenings on the CT scanner mobile unit and held ribbon-cutting ceremonies at the local union halls of the three gaseous diffusion sites. The kick-off ceremonies were a great success thanks to the local union staff that organized each event. All the events ...

B.C. Cancer Agency Protocol Summary LUNAVP Page 1 of 2 Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) with Cisplatin and Vinorelbine (Interim Version) Protocol Code : LUNAVP Tumour Group : Lung Contact Physician : Dr. Christopher Lee ELIGIBILITY : Advanced non-small cell lung cancer ECOG performance status of 0, 1 or 2 EXCLUSIONS : More than one previous chemotherapy regimen TESTS : Baseline: CBC & differential, platelets, creatinine, liver function tests, bilirubin Before each treatment: CBC and differential, platelets, creatinine If clinically indicated: bilirubin prior to each cycle PREMEDICATIONS : Antiemetic protocol for High Moderate emetogenic chemotherapy protocols as long as cisplatin dose is not = 50 mg. If cisplatin is = 50 mg use antiemetic protocol for highly ...

Tuition: $150.00 Name: _ (please print clearly) Social Security Number: MD DO ND RN PA ARNP Specialty _ Email: __ Mailing Addr ess: (or VMMC Mailstop) __ Daytime Phone Number: Or ganization: __ Check enclosed. Make check payable to: Virginia Mason Medical Center – CME Please char ge my VISA MASTERCARD AMEX Car d # _ Expiration Date: __ Signatur e__ AGENDA LUNG CANCER 2004 and BEYOND, April 30, 2004 REGISTRA TION LUNG CANCER 2004 and BEYOND Friday, April 30, 2004 Course Description This one-day conference will present the current recommendations for lung cancer screening and workup of the patient with pulmonary nodule. In addition, we will discuss current ...

NON–SMALL-CELL LUNG CANCER , MESOTHELIOMA, AND THYMOMA 123 CHAPTER 7 Non–small-cell lung cancer , mesothelioma, and thymoma Robert J. McKenna, Jr., MD , Benjamin Movsas, MD , Dong M. Shin, MD , and Fadlo R. Khuri, MD In the United States, lung cancer has been the leading cause of cancer death in men for years, and since 1988, it has become the number-one cause of cancer death in women. It is estimated that 171,900 new cases of lung cancer will be diagnosed in 2003, and 157,200 deaths due to this disease will occur. This exceeds the combined number of deaths from the second, third, and fourth leading causes of cancer (breast, prostate, and colon cancer , respectively). Lung cancer appears to develop from a stem cell that can differentiate along multiple lines. Although ...

lung cancer Methodological Aspects of Identifying Biomarkers:The Case of Microarray-Based Lung Cancer Diagnostics Constantin F. Aliferis M.D., Ph.D., Discovery Systems Laboratory, Department of Biomedical Informatics, Vanderbilt University Lung SPORE Research Conference 10-23-2003 Acknowledgments/Collaborators (alphabetic order) D. Hardin Ph.D. P. Massion M.D. A. Statnikov M.S. I. Tsamardinos Ph.D. Focus of this talk: Some Challenges in Using Array Gene Expression data and Data Analysis to Discover Potential Biomarkers Biomarkers = measurable molecular phenotypic parameters that characterize an organism ’ s state of health or disease, or a response to a particular therapeutic intervention (Negm et al. Trends Mol Med, 2002) Biomarkers are sought as instruments to help in ...

Vanderbilt-Ingram Cancer Center National Cancer Institute (NCI) SPORE in Lung Cancer - Pilot Project Application Instructions 1. Applications are solicited for pilot projects to conduct basic, translational or clinical research on the cause, prevention, detection or treatment of Lung Cancer . 2. Pilot project funding is open to all Vanderbilt University faculty members at the Assistant Professor level or higher. 3. Applications MUST be submitted on the enclosed “Application for Pilot Project Funds.” This packet includes a combined face page and budget page as well as pages for the budget justification, description of proposed research, references, biographical information and other support. Specific details regarding the application are outlined below: a) The minimum font size is 12 points. Be aware that as you fill in the fields, the page and border ...

Abstract. Elderly patients with lung cancer tend to have significant coexisting diseases and less aggressive treatment is often required. To investigate the clinicopathological features of non-small cell lung cancer (NSCLC) in elderly patients who were treated with radiotherapy, we reviewed the medical records at our division. Among the 189 patients 70 years or older between 1992 and 2001, 28 (14.8%) patients were treated with radiotherapy (elderly group). In the elderly group, there was a medical history of chronic obstructive pulmonary disease (COPD) (57.1%), cardiovascular disease (32.1%), diabetes mellitus (18.5%), malignant disease (18.5%), or cerebrovascular disease (10.7%). Moreover, in the elderly group, 17 (60.7%) patients had two or three coexisting diseases. There was statistical difference between the elderly group and the younger group (less than 70 years patients) ...

Imaging Lung Cancer Edward F. Patz, Jr Imaging plays an essential role in diagnosing, staging, and following patients with lung cancer . Most tumors are found on chest radiographs, although further eval- uation with thoracic computed tomography is per- formed to stage local disease. Additional radiologic studies, including radionuclide bone scan, brain com- puted tomography, or magnetic resonance imaging are typically used in select patients in the search for thoracic More recently, whole body positron emission tomography imaging has become an extremely useful tool in evaluating the primary tumor, regional lymph nodes, and distant sites of disease in lung cancer patients. With continued improvements in diagnostic imaging modalities, definition of risk groups, discovery of molecular markers, and development of new therapeutic strategies, improved survival ...

Abstract. Splenic metastasis from a lung cancer is infrequently noted, however, the pattern of the metastasis has not been studied, thus we conducted a retrospective study. Twelve of the consecutive 997 patients with lung cancer , who were admitted to our division, developed splenic metastasis. The pattern of splenic metastasis involved solitary nodule in 7 patients (58.3%); multiple nodules in 4, and microscopic metastasis in 1. All of the 12 patients had other abdominal organ metastasis. Splenic mass accompanying metastasis to other abdominal organs in a patient with a known lung cancer should be regarded as a metastasis. Introduction Although numerous articles have reported cases of abdominal visceral metastasis from lung cancer (1,2), metastasis to the spleen from lung cancer is considered rare and usually is detected only at autopsy (3-5). And early ...

Abstract. Metastatic involvement of the peritoneum is not a very rare autopsy finding. Clinically, however, peritonitis carcinomatosis from a lung cancer is infrequently encountered and the pattern of the metastasis has not been studied. A total of 1041 patients with lung cancer who were admitted to our division over a 26-year period were retrospectively analyzed. Twelve (1.2%) of the 1041 patients with advanced lung cancer developed peritoneal carcinomatosis in their clinical courses. The incidence of peritoneal carcinomatosis was high in patients with large cell carcinoma and adenocarcinoma. Six and 9 of the 12 patients had metastases in intra-abdominal sites and pleural seeding, respectively. The median survival time from the diagnosis of peritoneal carcinomatosis was 2 months. Ascites accompanying metastasis to abdominal organs and pleural seeding in a patient with a known ...

KIMBA ROXBY DOWNS (M) COOBER PEDY (DC) UNINCORP. FAR NORTH UNINCORP. FLINDERS RANGES ROBE BERRI CLARE HAWKER CEDUNA TANUNDA WHYALLA MENINGIE WILLUNGA MAITLAND PORT PIRIE BORDERTOWN PORT LINCOLN PETERBOROUGH PORT AUGUSTA MOUNT GAMBIER PORT BROUGHTON 0 100 200 50 Kms Lung Cancer Mortality in South Australia, 1991-2000 by Statistical Local Areas GAWLER GLENELG MODBURY WILLUNGA ADELAIDE WOODVILLE ELIZABETH MOUNT BARKER BEDFORD PARK NOARLUNGA CENTRE Annual Mortality/100,000 0 - 25 26 - 30 31 - 40 41 - 150 Towns Statistical Local Areas Produced by: Data Analysis and Consulting Unit, Information Management Services, and Epidemiology Branch, Department of Human Services. Data Sources: Cancer ...

Diesel Emissions and Lung Cancer : Epidemiology and Quantitative Risk Assessment A Special Report of the Institute’s Diesel Epidemiology Expert Panel Health Effects Institute June 1999 Page 2 The Health Effects Institute, established in 1980, is an independent and unbiased source of information on the health effects of motor vehicle emissions. HEI supports research on all major pollutants, including regulated pollutants (such as carbon monoxide, ozone, nitrogen dioxide, and particulate matter), and unregulated pollutants (such as diesel engine exhaust, methanol, and aldehydes). To date, HEI has supported more than 200 projects at institutions in North America and Europe and published over 100 Research Reports. Consistent with its mission to serve as an independent source of information on the health effects of motor vehicle pollutants, ...

132 SECTION TWELVE 114. Primary Lung Cancer • 15% overall 5-year survival for all lung cancers –NSCLC stage I: 60–70% 5-year survival –NSCLC stage II: 40% 5-year survival –NSCLC stage III/IV: <15% 5-year survival –Untreated SCLC survival < 6 month –Chemotherapy-treated SCLC <10% 5-year survival (however, 50% of patients have an initial positive response) • Complications of unresectable tumors include pleural effusion, post-obstructive pneumonia, airway obstruction, bronchopleural fistula, and metastases • Complications of resected tumors include local or distant recurrence, empyema, bronchopleural fistula, and post-thoracotomy pain • SCLC management is almost exclusively non-surgical –Responds well to combination chemotherapy –Radiation to symptomatic sites for palliation –Prophylactic brain radiation is often used as >80% of patients ...

MICROARRAY EXPRESSION ANALYSIS IN THE STUDY OF LUNG TUMORIGENESIS: OF MICE AND MAN Mark W. Geraci, MD This presentation focuses predominantly on the use of Affymetrix microarrays to study of lung cancer . For the purposes of this presentation, all tumor samples are compared to adjacent uninvolved lung in order to define genes that discriminate tumor from adjacent lung . There are several data issues specific to the platform, which include, 1) data filtering for the presence and absence of genes 2) variability filtering within a class, 3) the issue of fold change as a marker of significance, and 4) the different feature analysis protocols. The evaluation of human non-small cell lung cancer samples have yielded insight into the biology of tumor progression, and aided in the development of biomarkers of the disease. The widespread utilization of tissue microarrays allows for ...

Type in the following URL: https://cs.sciencedirect.com/activate/iaslc/members Note that “https://” MUST be entered for this URL – “http://” will not work. This is to ensure that your registration details are secured when you enter them into the registration form. Step by Step guide to your free online access! To activate access and to create your personal account as a member of International Association for the Study of Lung Cancer , you will need your Elsevier Customer Reference Number.Your Customer Reference Number can be found on the mailing label of each paper issue of the journal. Step 1 Step 2 The next step is to complete your user profile. You will be asked to fill out the form and choose your own password. A username will be assigned to you. You will be notified of this on the following page and by email ...

October 9, 2002 news release New procedures available for lung cancer patients Lung cancer patients are benefiting from new interventional bronchoscopy procedures in the Calgary Health Region. Dr. Alain Tremblay, a respirologist at Foothills Hospital and one of few physicians in Canada who performs these procedures, offers lung cancer patients an opportunity to have tumors removed by guiding a catheter and camera through the trachea in a minimally invasive procedure. Prior to these procedures, the only available treatment for lung cancer patients was radiation therapy. "These procedures improve the quality of life, and in some cases can extend length of life," says Tremblay. "We are able to remove blockages in the lungs caused by inflammatory disease, tumors or scarring with procedures that reduce hospitalization stays from two weeks to as soon as the next day." The procedures ...

Molecular Signatures in Biopsy Specimens of Lung Cancer Alain C. Borczuk, Lori Shah, Gregory D. N. Pearson, Kristin L. Walter, Liqun Wang, John H. M. Austin, Richard A. Friedman, and Charles A. Powell Department of Pathology, Department of Medicine, Department of Radiology, Department of Biomedical Informatics, and Herbert Irving Comprehensive Cancer Center, Columbia University College of Physicians and Surgeons, New York, New York Gene expression profiles of resected tumors may predict treatment response and outcome. We hypothesized that profiles derived from lung tumor biopsies would discriminate tumor-specific gene signa- tures and provide predictive information about outcome. Lung car- cinoma specimens were obtained from 23 patients undergoing computed tomography-guided transthoracic biopsy or endobron- chial brushing for undiagnosed nodules. Excess tissue was processed ...

The incidence of lung cancer in men is high but has decreased by 21% since 1989-91, and in women increased up to 1989-91 and has been stable since. Mortality from lung cancer followed similar trends reducing by 17% in men since 1980-82 and increasing by 46% in women between 1980-82 and 1989-91 and remaining stable since. Lung Cancer is the leading cause of cancer mortality amongst men and the second highest cause of cancer mortality amongst women in South Australia. Background notes Lung Cancer Page 2 Male Lung Cancer - Incidence and Mortality* 1977-2000 All Ages Source - SA Cancer Registry Data 0 10 20 30 40 50 60 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 Year ...

1 ORIGINAL ARTICLE Long-term survival in lung cancer after surgical treatment: is gender a prognostic factor? C AROLINA M A BREU 1 , J OSÉ M IGUEL C HATKIN 1 , C ARLOS C EZAR F RITSCHER 1 , M ÁRIO B ERNANRDES W AGNER 1 , J OSÉ A L F IGUEIREDO P INTO 1 Background: In a prior study, we found a possible correlation between gender and prognosis in non-small cell stage I lung cancer (NSCLC), showing a better survival rate among females. This is in accordance with some other reported studies. The purpose of this study was to further clarify the role of gender as a possible prognostic factor in NSCLC. ...

A206: Lung cancer tissues (formalin fixed) For research use only Specifications: •No. of cases: 40 •Tissue type: Lung cancer tissues •No. of spots: 2 spots from each cancer case (80 spots) 4 non-neoplastic spots (4 spots) •Total spots: 84 •Corresponding normal tissues with cancers: Yes •Diameter: 1.0 mm Documents: •Product specification: layout, summary of tissue spots •H&E stained images •Detailed pathological information Layout: Page 2 A206: Lung cancer tissues (formalin fixed) For research use only Summary of tissue spots No. Sex Age Key Word TNM Stage 1 1, 2 f 57 adenocarcinoma T2N2M0 (IIIA) 2 3, 4 m 68 adenocarcinoma T1N0M1 (IV) 3 5, 6 m 71 ...

VICC THO 0214 Phase II: OSI- 774 (Tarceva) in Pts with Advanced BAC Bronchioloalveolar 1st or 2nd Line 1st or 2nd Line Mesothelioma Lung Cancer Miscellaneous Clinical Trials VICC SAR 0269 Phase II: SDX-102 for NSCLC pts with MTAP- deficient cancer K E Y Pending Suspended Open Revised Team Leader Signature and Date Revised 5/17/04

www.datamonitor.com Stakeholder Insight: Lung Cancer Third-generation Cytotoxics to Dominate the Lung Cancer Market A Datamonitor In-Depth Analysis Published: Feb-04 Product Code: DMHC1906 Use this In-Depth Analysis to Assess the size of the drug-treated population of lung cancer in the seven major markets Providing you with: • Analysis of Lung cancer treatment based on a survey of 152 clinical oncologists and pulmonologists, conducted in the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK) • Diagnosis patterns of SCLC and NSCLC in the seven major markets, including stage distribution and physician types responsible for diagnosis • Percentage use of various treatment modalities for SCLC and NSCLC by stage Page 2 Stakeholder ...